A prior authorization denial for Humira or an adalimumab biosimilar is not a final answer. It's the beginning of a process — and patients who understand that process and pursue it systematically succeed more often than those who don't.
Here's a practical, step-by-step guide to appealing a denial.
Why Denials Happen
Humira and adalimumab biosimilars are specialty biologics with list prices well above most insurers' preferred cost thresholds. Most plans require prior authorization before covering them, and denials commonly happen for a few reasons:
- Step therapy requirements: The plan requires that you try and fail a different treatment first (often methotrexate for RA, or 5-ASA drugs for IBD)
- Non-preferred drug: The specific product your doctor prescribed isn't on the formulary's preferred tier
- Missing documentation: The prior auth request didn't include all required clinical information
- Coverage exclusion: Your plan excludes the indication (e.g., covers adalimumab for RA but not psoriasis)
Each of these has a different appeal strategy.
Step 1: Get the Denial in Writing and Read It Carefully
You are entitled to a written explanation of why your claim was denied. Request it in writing if it wasn't provided automatically. The denial letter will identify:
- The specific reason for denial (the code or language used matters)
- The appeals process and deadlines
- The clinical criteria the plan used to make its decision
Read this carefully. A step-therapy denial requires a different appeal than a formulary exclusion or a documentation gap.
Step 2: Contact Your Prescriber Immediately
Your prescriber's participation is essential to a successful appeal. Call their office and ask for their help with the prior authorization appeal. Specifically, you need:
- A letter of medical necessity — documenting your diagnosis, the clinical severity of your condition, why adalimumab is appropriate, and why alternatives are inadequate
- Documentation of any prior treatments you've tried (methotrexate, other biologics, conventional therapies) and why they failed or were contraindicated
- Lab results, disease activity scores, or imaging that supports the clinical case
- If relevant: documentation of stability on your current medication (if you're appealing a switch, not an initial denial)
Many prescriber offices deal with specialty biologic prior auths regularly. They may have a template letter or a staff member who handles these — ask specifically.
Step 3: File the Internal Appeal
Every insurance plan is required to provide an internal appeals process. The deadline is typically 60 to 180 days from the denial date, depending on your plan type and state.
Your appeal should include:
- Your prescriber's letter of medical necessity
- Supporting clinical records (diagnosis documentation, failed prior therapy records, lab values)
- The specific clinical criteria from your plan that you believe are met
- ACR or specialty society guidelines, if relevant to your condition
For step therapy denials specifically, many states have step therapy reform laws that require exceptions when:
- The required prior treatment is medically contraindicated for you
- The required prior treatment was previously tried and failed
- You were stable on your current medication before the plan changed its requirements
If any of these apply, state them explicitly in your appeal.
Internal appeal timeline: Standard reviews typically take 30–60 days. If your health situation is urgent, request an expedited review — which must be decided within 72 hours under federal law (for urgent cases).
Step 4: If the Internal Appeal Is Denied — External Review
If your internal appeal is denied, you have the right to an independent external review by a reviewer with no affiliation to your insurer. This is a federal right under the ACA (for commercial plans) and has state equivalents for Medicaid.
External reviewers are required to evaluate your appeal based on clinical evidence and plan terms, not on insurer cost preferences. External reviews overturn internal denials at a meaningful rate — particularly for specialty medications with strong clinical documentation.
Request external review within the deadline specified in your denial letter (usually 60 days).
Step 5: State Insurance Commissioner and Other Escalation
If you believe your insurer is acting in bad faith, violating state insurance laws, or not following the required appeals process, you can file a complaint with your state insurance commissioner. This creates a formal regulatory record and often prompts the insurer to reconsider.
For Medicare patients, the Office of Medicare Hearings and Appeals (OMHA) handles escalated Medicare drug coverage appeals.
If All Appeals Fail: Parallel Options
While your appeals are in process — or if they ultimately fail — you have parallel options:
Manufacturer Patient Assistance Programs: If your insurer won't cover adalimumab and you meet income eligibility criteria, PAPs from AbbVie (deadline July 1, 2026 for new apps) or biosimilar manufacturers can provide free medication.
Different formulation or biosimilar: If the specific product was denied, ask your prescriber whether a different FDA-approved adalimumab (on your plan's preferred tier) would be clinically appropriate.
Appeals advocacy organizations: Several nonprofit organizations offer free help with specialty drug appeals, including Patient Advocate Foundation and the HealthWell Foundation.
ClariMeds can evaluate your eligibility for applicable assistance programs in parallel with your appeals process — so cost doesn't become a barrier while you wait for a decision.
Check your options — about 5 minutes
This article contains general information about the insurance appeals process. It does not constitute legal advice. For complex situations, consider consulting a patient advocate or healthcare attorney.